Keiser P, Nassar N, Yazdani JB, Armas L, Moreno SA; International Conference on AIDS (15th : 2004 : Bangkok, Thailand).
Int Conf AIDS. 2004 Jul 11-16; 15: abstract no. TuPeB4540.
University of Texas Southwestern Medical Center, Dallas, United States
Background: Non-White patients are under-represented in clinical trials. There is little data comparing the effectiveness of anti-retroviral agents in non-white populations in the USA. Clinical trials have demonstrated better response rates in patients treated with efavirenz compared to abacavir and to nelfinavir. There is insufficient data in these studies to determine if there are different responses rates in African Americans and Hispanic subjects. In addition, there are no comparative trials of anti-retroviral agents in solely in non-white subjects. Methods: The Parkland HIV Database was queried for anti-retroviral naive HIV-1 infected African-americans or Hispanics who were treated with Combivir plus either efavirenz, nevirapine, nelfinavir or abacavir. The primary endpoint was time to virologic failure defined as 2 consecutive HIV-1 RNA >400 copies after an HIV-1 RNA >400 copies or failure to achieve an HIV-1 RNA< 400 cpm as measured by Kaplan Meier analysis. Potential Co-varia tes such as gender, illicit drug use, mental illness, Spanish as primary language, and adherence were analyzed through by the Cox proportional hazards model. Results: 653 patients were identified. 438 were African American and 215 were Hispanic. The best time to treatment failure was observed in patients treated with efavirenz; differences in other regimens were not statistically significant. Cox proportional hazards adjusted for race, gender, mental illness, baseline CD4 count and baseline HIV-1 RNA found the best time to treatment failure in patients treated with efavirenz regimens. [table: see text] Conclusions: African Americans and Hispanic patients treated with Combivir-efavirenz had best time to treatment failure. This result was independent of race, gender, CD4 count and baseline HIV-1 RNA. These results are consistent with clinical trials comparing that have a majority of non-minority subjects.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- Anti-Retroviral Agents
- CD4 Lymphocyte Count
- Combivir
- Dideoxynucleosides
- Drug Combinations
- HIV Infections
- HIV Protease Inhibitors
- HIV-1
- Humans
- Lamivudine
- Nelfinavir
- Nevirapine
- Oxazines
- Reverse Transcriptase Inhibitors
- Treatment Failure
- Zidovudine
- abacavir
- efavirenz
Other ID:
UI: 102282362
From Meeting Abstracts